Advertisement


Daniel F. Hayes, MD, on Liquid Biopsies to Detect and Monitor Oligometastases

2021 ASTRO Annual Meeting

Advertisement

Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center, discusses whether liquid biopsies can provide insight into the challenge of curing metastatic breast and possibly other cancers, how oligometastases are similar to a primary cancer, and why some kinds of local therapy for widespread disease might improve survival and lead to a cure.



Related Videos

Prostate Cancer

Howard M. Sandler, MD, on Prostate Cancer Highlights: An Expert Perspective

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses whether hypofractionation can be safely employed in the post-prostatectomy setting and the role of short-term hormone therapy in the management of intermediate-risk prostate cancer with radiotherapy.

Prostate Cancer

Amar U. Kishan, MD, on Prostate Cancer: Impact of Androgen-Deprivation Therapy With Radiotherapy

Amar U. Kishan, MD, of the University of California, Los Angeles, discusses findings from a meta-analysis of clinical trials in patients with localized prostate cancer. The phase III results suggest that the use of androgen-deprivation therapy (ADT) or prolonged adjuvant ADT with radiotherapy may benefit patients with localized prostate cancer. Further biomarkers are needed to better personalize treatment intensification (Abstract 8).

CNS Cancers

Erin Murphy, MD, on Low-Grade Glioma: Neurocognitive Function Following Treatment

Erin Murphy, MD, of Cleveland Clinic, discusses new data that show no apparent difference in cognitive performance up to 2 years post-treatment among adults with low-grade glioma who were treated with concurrent radiotherapy and temozolomide (Abstract 3258).

Head and Neck Cancer

David A. Palma, MD, PhD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs Surgery

David A. Palma, MD, PhD, of Ontario’s London Health Sciences Centre, discusses results of the ORATOR2 study, which compared two treatment options that could be de-escalated for patients with HPV-associated oropharyngeal squamous cell carcinoma: a lower-dose radiation approach (6 weeks instead of 7, often with chemotherapy) vs a transoral surgical approach (with low-dose radiation afterward, for 5 weeks) (Abstract LBA2).

Solid Tumors

Aadel A. Chaudhuri, MD, PhD, on Personalizing Treatment for Oligometastatic Cancer

Aadel A. Chaudhuri, MD, PhD, of Washington University School of Medicine in St. Louis, discusses circulating tumor DNA, which has the potential to better personalize treatment for patients with oligometastatic cancer and help clinicians determine whether to offer systemic therapy alone or curative-intent local consolidative therapy.

Advertisement

Advertisement




Advertisement